Victory Capital Management Inc. Decreases Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Victory Capital Management Inc. decreased its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 0.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,570 shares of the company’s stock after selling 1,633 shares during the quarter. Victory Capital Management Inc.’s holdings in Ginkgo Bioworks were worth $1,463,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Russell Investments Group Ltd. increased its holdings in shares of Ginkgo Bioworks by 9,440.6% during the first quarter. Russell Investments Group Ltd. now owns 31,961 shares of the company’s stock valued at $37,000 after acquiring an additional 31,626 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its position in Ginkgo Bioworks by 260.2% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 451,383 shares of the company’s stock worth $525,000 after acquiring an additional 326,070 shares during the period. Paloma Partners Management Co purchased a new stake in Ginkgo Bioworks during the 1st quarter valued at about $28,000. Caxton Associates LP acquired a new position in shares of Ginkgo Bioworks in the first quarter valued at about $438,000. Finally, Cetera Investment Advisers raised its stake in shares of Ginkgo Bioworks by 2,683.7% in the first quarter. Cetera Investment Advisers now owns 2,264,107 shares of the company’s stock worth $2,626,000 after purchasing an additional 2,182,773 shares during the last quarter. 78.63% of the stock is currently owned by hedge funds and other institutional investors.

Ginkgo Bioworks Stock Performance

DNA opened at $8.13 on Tuesday. The firm has a market cap of $467.31 million, a PE ratio of -0.60 and a beta of 1.09. The company has a fifty day moving average price of $7.84. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.26 and a 1 year high of $75.20.

Analyst Ratings Changes

Several brokerages recently weighed in on DNA. BTIG Research increased their price target on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a “sell” rating in a report on Friday, August 23rd. TD Cowen boosted their target price on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, September 20th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, Ginkgo Bioworks has a consensus rating of “Hold” and a consensus target price of $4.58.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.